IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
April 2005 not to de velop Xenical af ter com plet ing phase II tri als, cit ing a need for ad di tional tri als un der
lo cal guide lines. An a lysts at West LN Pan mure be lieve that the pos i tive side ef fect pro file and low cost of
the prod uct should make the prod uct com pet i tive. Clin i cal re sults so far in di cate that cetilistat is better
tol er ated than Xenical. Ac cord ing to IMS, the only antiobesity prod uct mar keted in Ja pan in the year end -
ing Sep tem ber 2008 is an am phet amine type drug Teronac (mazindol), available in Japan since 1992
and marketed by Novartis.
ILAPRAZOLE is a pro ton pump in hib i tor. In Sep tem ber 2005, the TAP joint ven ture be tween Takeda and
Abbott ac quired world wide rights out side South Ko rea and China. The TAP jv was con cluded in May 2008
and Takeda will re tain this prod uct. Phase III tri als are on go ing in var i ous Asian coun tries, and phase II
tri als are re ported in the US and Canada.
Orig i na tor Il Yang (South Ko rea) has launched the prod uct China in May 2008.
Li cens ing: Il Yang has li censed-out Chi nese rights to Livzon (China).
NOVONORM/PRANDIN (repaglinide) is an oral agent for the treat ment of non-in su lin de pend ent di a -
be tes (Type 2). Repaglinide was orig i nally de vel oped by Boehringer Ingelheim (Ger many) and li censed
out to Novo Nordisk (Den mark), which has launched it in a num ber of mar kets world wide. In 1999, Novo
Nordisk and Takeda agreed to co-mar ket repaglinide in Ja pan. Repaglinide has been launched in the USA,
the EU and var i ous other mar kets. Repaglinide was re ported to be in phase III tri als in Ja pan with
Dainippon Sumitomo who signed an agree ment with Novo Nordisk in 2004.
VEDOLIZUMAB (MLN 002), a hu man ized monoclonal an ti body that in hib its the in ter ac tion be tween the
alpha4beta7 integrin on lym pho cytes and the mucosal adressin mol e cule, MAdCAM-1, which is pre dom i -
nant on mucosal tis sue in the gut, is be ing de vel oped as an in ject able treat ment for ul cer ative co li tis and
Crohn’s dis ease. Two phase III tri als were ini ti ated in Jan u ary 2009, as part of the GEM INI pro gram that
will study vedolizumab in ul cer ative co li tis and Crohn’s dis ease, en roll ing 2,000 pa tients from 40 coun -
tries (in clu sion of Ja pan not yet de cided) with mod er ate-to-se vere dis ease, un re spon sive to stan dard
ther a pies. The tri als will each con sist of a six-week in duc tion phase fol lowed by 46 weeks of main te nance
ther apy with vedolizumab iv in fu sion. Pa tients will be given the op por tu nity to con tinue treat ment for up
to 100 weeks as part of a fol low-up study eval u at ing the safety and ef fi cacy of the agent. Takeda in tends
to file for ap proval in Ja pan, the US and Eu rope in 2011, and hopes this will fur ther en hance its pres ence
in the market for GI drugs which it has established with the PPI lansoprazole.
SYR 472, an orally ad min is tered dipeptidyl peptidase IV (DDP-IV) in hib i tor, as a po ten tial treat ment for
type II di a be tes. The com pound was in phase II de vel op ment in the USA and the EU and phase I in Japan
in 2009.
TAK 379, an in su lin sensitizer was re ported to be in phase II tri als with Takeda in the US and Eu rope and
phase I in Ja pan for di a be tes mellitus in 2009.
TAK 875, an oral glu cose-de pend ent in su lin secretagogue, for the treat ment of di a be tes was re ported to
be in phase II tri als with Takeda in Ja pan for di a be tes in 2009.
TAK 100, an orally ad min is tered dipeptidyl peptidase IV (DDP-IV) in hib i tor, as a po ten tial treat ment for
type II di a be tes, was re ported to be in phase I de vel op ment in 2009.
MLN 0415, is an oral small mol e cule in hib i tor of IKK2, with po ten tial ap pli ca tion in the treat ment of in -
flam ma tory dis eases, in clud ing rheu ma toid ar thri tis, mul ti ple scle ro sis, chronic ob struc tive pul mo nary
dis ease (COPD) and in flam ma tory bowel dis ease. Phase I eval u a tion was un der way with Millennium (now
Takeda) in 2009.
© 2009 IMS Health In cor po rated or its af fil i ates Page 62